TW230206B - - Google Patents

Info

Publication number
TW230206B
TW230206B TW082100802A TW82100802A TW230206B TW 230206 B TW230206 B TW 230206B TW 082100802 A TW082100802 A TW 082100802A TW 82100802 A TW82100802 A TW 82100802A TW 230206 B TW230206 B TW 230206B
Authority
TW
Taiwan
Application number
TW082100802A
Other languages
Chinese (zh)
Inventor
E Mulle Ulrich
Muller-Gliemann Marrhias
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW230206B publication Critical patent/TW230206B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
TW082100802A 1992-02-27 1993-02-06 TW230206B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4206045A DE4206045A1 (de) 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone

Publications (1)

Publication Number Publication Date
TW230206B true TW230206B (cg-RX-API-DMAC10.html) 1994-09-11

Family

ID=6452730

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082100802A TW230206B (cg-RX-API-DMAC10.html) 1992-02-27 1993-02-06

Country Status (18)

Country Link
US (1) US5254543A (cg-RX-API-DMAC10.html)
EP (1) EP0557843A3 (cg-RX-API-DMAC10.html)
JP (1) JPH0641081A (cg-RX-API-DMAC10.html)
KR (1) KR930017898A (cg-RX-API-DMAC10.html)
CN (1) CN1078468A (cg-RX-API-DMAC10.html)
AU (1) AU653288B2 (cg-RX-API-DMAC10.html)
CA (1) CA2090267A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ15793A3 (cg-RX-API-DMAC10.html)
DE (1) DE4206045A1 (cg-RX-API-DMAC10.html)
HU (1) HUT64057A (cg-RX-API-DMAC10.html)
IL (1) IL104843A0 (cg-RX-API-DMAC10.html)
MX (1) MX9300766A (cg-RX-API-DMAC10.html)
MY (1) MY129973A (cg-RX-API-DMAC10.html)
NZ (1) NZ245999A (cg-RX-API-DMAC10.html)
PL (1) PL297870A1 (cg-RX-API-DMAC10.html)
SK (1) SK14593A3 (cg-RX-API-DMAC10.html)
TW (1) TW230206B (cg-RX-API-DMAC10.html)
ZA (1) ZA931370B (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
JPH06306073A (ja) * 1992-12-10 1994-11-01 Japan Tobacco Inc ニコチン誘導体の光学分割法
WO2000058304A1 (en) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
GB0514686D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CN1985878B (zh) * 2005-12-20 2011-06-22 广州王老吉药业股份有限公司 一种治疗消化性溃疡的药物组合物及其制备方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
NZ584148A (en) * 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
RU2492170C9 (ru) * 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011006245A (es) 2008-12-23 2011-07-13 Hoffmann La Roche Dihidropiridona-amidas como moduladores de p2x7.
SG172382A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone ureas as p2x7 modulators
CA2745864A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
SG172385A1 (en) 2008-12-23 2011-08-29 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
EP0403159B1 (en) * 1989-06-14 2000-03-01 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
KR950009860B1 (ko) * 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
KR100196559B1 (ko) * 1990-06-19 1999-06-15 기따사또 이찌로 안지오텐신ii 길항작용을 함유하는 피리딘 유도체

Also Published As

Publication number Publication date
EP0557843A2 (de) 1993-09-01
CZ15793A3 (en) 1993-12-15
EP0557843A3 (en) 1993-12-01
CN1078468A (zh) 1993-11-17
US5254543A (en) 1993-10-19
HUT64057A (en) 1993-11-29
ZA931370B (en) 1993-03-23
SK14593A3 (en) 1993-10-06
PL297870A1 (en) 1993-10-04
JPH0641081A (ja) 1994-02-15
HU9300545D0 (en) 1993-05-28
IL104843A0 (en) 1993-06-10
CA2090267A1 (en) 1993-08-28
NZ245999A (en) 1995-10-26
MX9300766A (es) 1993-08-01
MY129973A (en) 2007-05-31
DE4206045A1 (de) 1993-09-02
AU653288B2 (en) 1994-09-22
AU3377093A (en) 1993-09-02
KR930017898A (ko) 1993-09-20

Similar Documents

Publication Publication Date Title
DK0574087T3 (cg-RX-API-DMAC10.html)
BR9207065A (cg-RX-API-DMAC10.html)
DK0553681T3 (cg-RX-API-DMAC10.html)
DK0581129T3 (cg-RX-API-DMAC10.html)
DK0574276T3 (cg-RX-API-DMAC10.html)
DK0571874T3 (cg-RX-API-DMAC10.html)
DK0564197T3 (cg-RX-API-DMAC10.html)
DK0596569T3 (cg-RX-API-DMAC10.html)
DK0576097T3 (cg-RX-API-DMAC10.html)
DK0559942T3 (cg-RX-API-DMAC10.html)
DK0590732T3 (cg-RX-API-DMAC10.html)
AU631518B2 (cg-RX-API-DMAC10.html)
AU2098792A (cg-RX-API-DMAC10.html)
AU2629492A (cg-RX-API-DMAC10.html)
CN3012489S (cg-RX-API-DMAC10.html)
AU1933792A (cg-RX-API-DMAC10.html)
AU1935292A (cg-RX-API-DMAC10.html)
AU2053892A (cg-RX-API-DMAC10.html)
AU1813892A (cg-RX-API-DMAC10.html)
AU2286392A (cg-RX-API-DMAC10.html)
AU1737992A (cg-RX-API-DMAC10.html)
AU2619992A (cg-RX-API-DMAC10.html)
AU2620092A (cg-RX-API-DMAC10.html)
AU1711092A (cg-RX-API-DMAC10.html)
AU1405592A (cg-RX-API-DMAC10.html)